About Stoic Bio

David Sheehan is the Founder, President, and CEO of Stoic Bio. He has led the development of novel capital equipment that radically changes the delivery of cell culture media, with a focus on sustainability. Prior to Stoic Bio, Dave was COO of Volcano Corporation, a publicly held life sciences company that was sold to Philips for $1.2 billion. Previous to Volcano, Dave was the CEO of Digirad, a cardiovascular imaging company that he took public in 2004, and in leadership positions at Baxter and Haemonetics. Dave also founded and is currently the CEO of Nucleus Biologics, (Stoic Bio's sister company), where he leads the development of innovative cell culture tools to simplify and accelerate the design, customization, and ordering of cell culture media products. Dave holds an MBA from The Tuck School at Dartmouth College and a BS in Mechanical Engineering from Worcester Polytechnic Institute.

Will has over 30 years of experience in financial and business leadership roles across a diverse range of industries, including wireless technologies, internet of things devices, and cosmeceuticals. Will serves as CFO for both Stoic Bio and sister company Nucleus Biologics. Previously, Will was the Senior VP of Finance and Operations for SENTE, and before that, was the CFO of LocusTraxx, leading the company to a successful acquisition exit. Will also spent 12 years at Qualcomm in various leadership roles across multiple divisions including new business development, finance lead for the successful acquisition of a business from Alcatel, and leading international finance and business operations for Qualcomm’s Omnitracs division. Will has a BS degree in accounting from Purdue University and an MBA in Finance with honors from the University of North Texas.

Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry prior to joining Stoic Bio and its sister company, Nucleus Biologics, as Vice President of Marketing. Most recently, Dr. Taylor was the Director of Global Marketing at HemaCare, supporting the needs of the cellular therapy industry. Prior to HemaCare, Dr. Taylor spent 11 years at PerkinElmer supporting in vivo imaging platforms and has held leadership roles in technical support, product management, and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.

Ben Weaver is the Chief Financial Officer of Tavistock Group, a dedicated investment firm for an institutional single-family office. He is also a member of the firm’s Executive Committee and serves as a Senior Managing Director of the firm. Mr. Weaver joined the Tavistock Group in early 2019 as Managing Director. Some of Tavistock’s notable investments: include the top tier English Premier League football club, Tottenham Hotspur; UK’s leading operator of managed pub restaurants, Mitchells & Butlers plc; Lake Nona, the innovative, 17-square-mile, master-designed community in Orlando, Florida; resort and private club communities of Albany in The Bahamas, Lake Nona Golf & Country Club and Isleworth Golf & Country Club in Orlando, Florida; agriculture company, Australian Agriculture Company (AACo); international hospitality real estate company, Nexus Luxury Collection; U.S.-based boutique fine dining company, Tavistock Restaurant Collection; and Mexican sporting goods company, Typhoon Sports Coalition. Prior to joining Tavistock Group, Mr. Weaver spent 15 years in the aerospace and defense sector, last serving as the President of BBA Aviation US Holdings and the Chief Financial Officer for BBA Aviation Flight Support. He has a broad range of experience including corporate governance, financial accounting, treasury management, operational and strategic planning, and mergers and acquisitions. He received his Bachelor of Science in Business Administration as well as his Master in Business Administration from John Carroll University.

Dr. Alexandra Silverton is an assistant professor at University of Central Florida and a board-certified Internal Medicine physician. Dr. Silverton also serves as Medical Director for Tavistock Development Company in Lake Nona’s Health and Life Sciences cluster. Prior to joining Tavistock in 2019, Dr. Silverton worked as an assistant professor and an academic hospitalist at both Tulane University and Emory University. Dr. Silverton received her Bachelor of Science Degree in Biology from Duke University and her MD from Emory University School of Medicine. Dr. Silverton also holds a Master’s degree in Public Health from the Rollins School of Public Health at Emory University. Dr. Silverton completed her Internal Medicine residency at New York University (NYU).

Alan Gold served as Chairman, President and Chief Executive Officer of BioMed Realty Trust, Inc. (formerly NYSE: BMR), a REIT specializing in acquiring, leasing, developing, and managing laboratory and office space for the life science industry, from its inception in 2004 through the sale of the company to affiliates of Blackstone Real Estate Partners VIII L.P. in January 2016. Mr. Gold also served as Chairman, President, and Chief Executive Officer of BioMed Realty’s privately-held predecessor, Bernardo Property Advisors, Inc., from August 1998 until August 2004. In addition, Mr. Gold was a Co-Founder and served as President and a Director of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT, from its predecessor’s inception in 1994 until August 1998. Mr. Gold is Mexican American and currently serves as a member of the board of trustees for the Salk Institute for Biological Studies, a research organization dedicated to fundamental research in biology and its relation to health. Mr. Gold received his Bachelor of Science degree in Business Administration and his Master of Business Administration from San Diego State University.

Neil has more than 30 years of business experience with emphasis on operations, legal, tax, investments, and finance. Neil has worked with the biopharmaceutical industry since 2004. In addition, Neil has worked at various multinational companies, including Tavistock Group, Arthur Andersen, and Amoco Corporation. Neil received his Juris Doctor from the University of Pennsylvania Law School and his Bachelor of Science in Accountancy from the University of Illinois.

David Sheehan is the Founder, President, and CEO of Stoic Bio. He has led the development of novel capital equipment that radically changes the delivery of cell culture media, with a focus on sustainability. Prior to Stoic Bio, Dave was COO of Volcano Corporation, a publicly held life sciences company that was sold to Philips for $1.2 billion. Previous to Volcano, Dave was the CEO of Digirad, a cardiovascular imaging company that he took public in 2004, and in leadership positions at Baxter and Haemonetics. Dave also founded and is currently the CEO of Nucleus Biologics, (Stoic Bio's sister company), where he leads the development of innovative cell culture tools to simplify and accelerate the design, customization, and ordering of cell culture media products. Dave holds an MBA from The Tuck School at Dartmouth College and a BS in Mechanical Engineering from Worcester Polytechnic Institute.

Rob Friel served as the chairman and chief executive officer of PerkinElmer, a global leader in life sciences with a mission of innovating for a healthier world, from February, 2008 until his retirement in December 2019. From August 2007 to January, 2019, Mr. Friel also served as PerkinElmer's president. Since joining PerkinElmer in February 1999 as chief financial officer, Mr. Friel also held roles as chief operating officer and president of PerkinElmer's life and analytical sciences unit. Prior to joining PerkinElmer, he held senior management positions with AlliedSignal, now Honeywell International. Mr. Friel currently serves as a member of the board of directors of West Pharmaceutical Services, NuVasive, New York Life, and chairman of the board of directors of Xylem. He also is an advisor to EQT Private Equity. Mr. Friel received a bachelor's degree from Lafayette College and a master's degree from Fairleigh Dickinson University.